Lake Street analyst Thomas Flaten raised the firm’s price target on Checkpoint Therapeutics (CKPT) to $7 from $4 and keeps a Buy rating on the shares after the company announced FDA approval of Unloxcyt for advanced cutaneous squamous cell carcinoma on Friday. The firm expects commercialization, likely in the second half of 2025, will be “via acquisition/partnership,” the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks